Outstanding issues in use of disease-modifying agents in rheumatoid arthritis
- PMID: 9929016
- DOI: 10.1016/s0140-6736(05)74938-2
Outstanding issues in use of disease-modifying agents in rheumatoid arthritis
Comment in
-
Leflunomide for active rheumatoid arthritis.Lancet. 1999 May 29;353(9167):1883; author reply 1883-4. doi: 10.1016/s0140-6736(05)75089-3. Lancet. 1999. PMID: 10359440 Clinical Trial. No abstract available.
Comment on
-
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.Lancet. 1999 Jan 23;353(9149):259-66. doi: 10.1016/s0140-6736(98)09403-3. Lancet. 1999. PMID: 9929017 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
